From the BBC World Service: AstraZeneca says it’ll invest $50 billion in the United States by 2030 as President Donald Trump threatens steep tariffs on drug imports.
Recent data from the Labor Department has shown that the price of foreign exports to the U.S. — before tariffs — has held steady over the last few months. That means U.S. importers are absorbing most of the tariff burden.
Businesses are having to figure out whether to absorb the cost of import taxes, pass them along, or a mixture of both approaches — all up and down supply chains.